We observed that a 7-day treatment with BZDRs downregulated anti-tumorigenic ECMs, S100B, COL6A6 and VIT, in both non-carcinoma (MCF10A) and carcinoma cells (MCF7 and MDA-MB231) (Fig. 4D–F) (blue boxes, * p < 0.05; ** p < 0.01; *** p < 0.005). Here, COL6A6 is linked to carcinoma.